Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 746 across all filing types
Latest filing 2020-06-15 Regulatory Filings
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2020
Regulatory Filings
2020-06-15 English
FORM 4 SUBMISSION
Director's Dealing
2020-06-10 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3, which is related to securities registration and capital raising. It is a correspondence about a regulatory filing and does not contain financial statements or detailed financial data. The document length is short (1009 characters) and it is a formal request rather than a report or announcement of results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and filings that do not fit other categories.
2020-06-10 English
Regulatory Filings 2020
Regulatory Filings Classification · 60% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify this document as any specific filing type. According to the fallback rule, when a document does not fit any specific category due to lack of information, it should be classified as a Regulatory Filing (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable. Therefore, the best classification is RNS with moderate confidence due to the lack of readable content.
2020-06-10 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC by Xenon Pharmaceuticals Inc. It is a registration statement under the Securities Act of 1933 for the purpose of registering securities for sale to the public. The document includes details about the types of securities to be registered, the maximum aggregate offering price, and the registration fee. It is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not merely an announcement of a report, so it is not RPA or RNS. Confidence is high given the clear identification of the form and purpose.
2020-06-03 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Xenon Pharmaceuticals Inc. on June 3, 2020. It registers additional common shares reserved for issuance under the company's Amended and Restated 2014 Equity Incentive Plan. The document includes details about the registration fee, incorporation by reference of previous filings, and signatures of company officers. Form S-8 is specifically used for registering securities to be offered under employee benefit plans, such as equity incentive plans. This type of filing is related to share issuance and capital changes rather than financial performance reports, management changes, or other categories. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is the actual registration statement, not just an announcement or reference to another report.
2020-06-03 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.